- Adverum Biotechnologies Inc To discuss the preliminary safety and efficacy data TranscriptFeb 08, 2024
- Adverum Biotechnologies Inc at HC Wainwright Ophthalmology Virtual Conference TranscriptAug 16, 2023
- Adverum Biotechnologies Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Adverum Biotechnologies Inc ADVM-022 Update Call TranscriptJul 22, 2021
- Q4 2020 Adverum Biotechnologies Inc Earnings Call TranscriptMar 01, 2021€107 (+7.00%)Earnings
- Adverum Biotechnologies Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Adverum Biotechnologies Inc Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call TranscriptNov 14, 2020
- Q2 2020 Adverum Biotechnologies Inc Earnings Call TranscriptAug 10, 2020€150 (-3.85%)Earnings
- Adverum Biotechnologies Inc Annual Shareholders Meeting TranscriptJun 23, 2020
- Adverum Biotechnologies Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Q1 2020 Adverum Biotechnologies Inc Earnings Call TranscriptMay 28, 2020€186 (+2.76%)Earnings
- Adverum Biotechnologies Inc to Present New Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD Call TranscriptMay 04, 2020
- Q4 2019 Adverum Biotechnologies Inc Earnings Call TranscriptMar 12, 2020€69 (-16.87%)Earnings
- Adverum Biotechnologies Inc Key Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call TranscriptFeb 09, 2020
- Adverum Biotechnologies Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Q3 2019 Adverum Biotechnologies Inc Earnings Call TranscriptNov 07, 2019€72 (+2.13%)Earnings
- Adverum Biotechnologies Inc Key Opinion Leader Discussion of Additional Cohort 1 Data from the Phase 1 OPTIC Trial TranscriptOct 12, 2019
- Adverum Biotechnologies Inc to Review Data Presented at Retina Society 2019 Conference Call TranscriptSep 12, 2019
- Q2 2019 Adverum Biotechnologies Inc Earnings Call TranscriptAug 08, 2019€107.02 (+2.47%)Earnings
Adverum Biotechnologies Inc at JPMorgan Healthcare Conference Transcript
Good afternoon, everyone. My name is [Ray Wang], and I am a member of the JPMorgan health care investment banking team. Thank you all for coming here today. And now it is my pleasure to introduce Leone Patterson, Chief Executive Officer of Adverum Biotechnologies.
All right. Thanks, everyone, for coming. Yes, we are a gene therapy company in the clinic. And today, my conversation is going to be with you around really the progress that we've made in the last 12 months, which has been significant. I mean I've been with the company for over 3 years, but I can tell you the progress that's been made in the last 12 months is really phenomenal. And what I'm going to cover today is that progress along with the clinical data that we just presented this past weekend at a scientific conference. And what are we talking about here is this lead program, ADVM-022, which we're now in the clinic. And this is transformative technology that we believe has the potential to change the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)